GNH USA

Europe — EMA

Lanreotide Viatris

GNH USA supplies Lanreotide Viatris (Lanreotide), a somatostatin analog for acromegaly and neuroendocrine tumor therapy. Request a quote for global supply.

Lanreotide

Request sourcing

1
Pack/s

What is Lanreotide?

Lanreotide, the active ingredient in Lanreotide Viatris, is a somatostatin analog presented as an injectable suspension for subcutaneous use. It works by inhibiting excess growth hormone secretion in adults with acromegaly and by controlling hormone‑related symptoms of certain neuroendocrine tumors. It is indicated for long‑term management in these patient populations.

GNH USA supplies Lanreotide Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our global distribution network ensures reliable delivery and regulatory compliance across multiple regions.

What is Lanreotide used for?

Lanreotide is a somatostatin analog used in endocrine‑related disorders.

Acromegaly: reduces excess growth hormone levels and helps normalize IGF‑1 concentrations. Neuroendocrine tumors: controls hormone‑related symptoms such as flushing and diarrhea. Carcinoid syndrome: alleviates flushing, abdominal pain and improves quality of life.

What are the side effects of Lanreotide?

Lanreotide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal pain - Diarrhea - Nausea - Injection site reactions - Hyperglycemia

Serious or Rare Side Effects: - Gallstone formation - Acute pancreatitis - Severe hypersensitivity reactions, including anaphylaxis

What precautions apply to Lanreotide?

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood glucose: hyperglycemia may occur, especially in diabetic patients. Assess gallbladder status: prolonged therapy can increase risk of gallstone formation. Evaluate pancreatic function: watch for signs of pancreatitis. Review cardiac status: rare arrhythmias have been reported. Avoid use in patients with known hypersensitivity to lanreotide or formulation components. Store at room temperature: keep in original container, protect from moisture and light.

What does Lanreotide interact with?

Lanreotide can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Octreotide: concurrent use may cause excessive hormone suppression. - Diazoxide: may reduce lanreotide efficacy. - Somatostatin receptor antagonists: may block therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: may require dose adjustment due to hyperglycemia. - Anticoagulants: monitor for bleeding if gastrointestinal side effects are present. - Hormonal contraceptives: possible reduced efficacy.

Frequently asked questions

What is Lanreotide Viatris used for?+
Lanreotide Viatris is indicated for the treatment of acromegaly, a condition caused by excess growth hormone, and for managing hormone‑related symptoms in patients with certain neuroendocrine tumors, including carcinoid syndrome. It helps normalize hormone levels and improve disease‑related symptoms.
How does lanreotide work?+
Lanreotide is a synthetic analogue of somatostatin. It binds to somatostatin receptors (mainly subtypes 2 and 5) on endocrine cells, inhibiting the release of growth hormone, insulin, glucagon and various gastrointestinal peptides. This receptor‑mediated blockade reduces hormone‑driven disease activity.
What is the usual dose of Lanreotide Viatris?+
The dosage and administration schedule for Lanreotide Viatris are determined by the prescribing clinician based on the patient’s condition, response and tolerability. The prescriber will select the appropriate injection frequency and amount according to current clinical guidelines.
Is Lanreotide Viatris safe in pregnancy or breastfeeding?+
Safety data for lanreotide during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss risks with their healthcare provider.
How do I order Lanreotide Viatris from GNH USA?+
To place an order, submit an enquiry on the Lanreotide Viatris product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain where applicable) and required import documentation.
How does Lanreotide compare with the main alternative drug?+
The primary alternative to lanreotide is octreotide, another somatostatin analogue. Both agents suppress growth hormone and tumor‑related hormone secretion, but lanreotide is formulated for less frequent dosing (often every 4 weeks) whereas octreotide typically requires more frequent injections. Choice depends on patient preference, tolerability and physician assessment.
How should Lanreotide Viatris be stored and handled?+
Lanreotide Viatris should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before administration, gently invert the vial to ensure a uniform suspension; do not shake vigorously.
How is Lanreotide Viatris given or administered?+
Lanreotide Viatris is administered as a subcutaneous injection. The healthcare professional prepares the injectable suspension according to the product’s instructions and injects it into the subcutaneous tissue, usually in the abdomen or thigh. Injection intervals are set by the prescriber, commonly every 4 weeks for chronic therapy.
What are the most serious risks to watch for while using Lanreotide Viatris?+
Serious adverse events include gallstone formation, acute pancreatitis and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for abdominal pain, persistent nausea, vomiting, jaundice, or signs of an allergic reaction, and they should seek immediate medical attention if these occur.
Who should not use Lanreotide Viatris?+
Lanreotide Viatris is contraindicated in individuals with known hypersensitivity to lanreotide or any component of the formulation. Caution is advised for patients with uncontrolled diabetes, severe gallbladder disease, or a history of pancreatitis. Pregnant or nursing women should only use it if clearly indicated by a physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lanreotide
Route
Subcutaneous Use
Manufacturer
Viatris Limited
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU